Podcasts about tirzepatide

Could medications originally designed for diabetes actually help treat addiction, eating disorders, and the biology of cravings?In this part 2 of 2-part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to dig deeper into the science, myths, and emerging uses of GLP-1 agonists. Dr. Wharton explains that these medications don't simply reduce appetite, they calm what he calls “food noise,” the constant mental pull toward eating that many people with obesity experience. This neurological effect has opened the door to exciting possibilities: early research suggests GLP-1 drugs may also reduce cravings for alcohol and other addictive behaviors.  Dr. Wharton also clarifies the confusing world of brand names. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are tirzepatide. The differences are largely about FDA indications and insurance coverage, not completely different medications.The episode tackles common fears patients and clinicians hear every day. Do these medications cause eating disorders? No, in fact, they may help treat them. Are the side effects dangerous? Usually not, and most are manageable with proper dosing. Is “Ozempic face” real? It's simply normal fat loss, not a drug-specific problem. Most importantly, Dr. Wharton reinforces a compassionate, evidence-based message: obesity is a chronic, biological disease, and GLP-1 medications are tools to treat it, just like medications for blood pressure or diabetes.Three Actionable TakeawaysGLP-1 Medications Affect the Brain as Much as the Stomach: These drugs reduce “food noise” and cravings, helping patients regain control over eating behaviors. Their impact is neurological, not simply about willpower or restriction.Side Effects Are Real—but Usually Manageable: Nausea, constipation, and GI symptoms are the most common issues, especially early on. Starting low and increasing doses slowly makes treatment far more tolerable.Treatment Decisions Should Be Individualized:  Not every patient must stay on these medications forever. Conversations about duration, goals, and expectations should be collaborative and tailored to each person.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.LinkedIn: linkedin.com/in/drseanwhartonWebsite: whartonmedicalclinic.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textCan Zepbound treat PCOS? That's the question this clinical trial will seek to answer, and we cover it exclusively on this week's On The Pen podcast.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

This episode covers: • Real Food Reset in U.S. Dietary Policy The new Dietary Guidelines for Americans 2025–2030 put real food back at the center of U.S. nutrition policy and take a direct swing at ultra processed foods, added sugar, and sugary drinks. Dave breaks down why this matters beyond personal dieting: these guidelines influence school meals, SNAP and WIC, federal feeding programs, and they shape what eventually shows up on labels and in public institutions. He also shares how biohackers can use this shift as leverage to push for better food environments in schools, workplaces, and hospitals. -Source: https://www.usda.gov/about-usda/news/press-releases/2026/01/07/kennedy-rollins-unveil-historic-reset-us-nutrition-policy-put-real-food-back-center-health • Drug Combo Extends Lifespan of Frail Old Mice by 73% A new aging study found that combining oxytocin with a compound called A5i extended the remaining lifespan of frail elderly male mice by 73%, while also improving function and tissue health. Dave explains why this is a big signal for the future of longevity medicine: stacking targeted interventions can outperform single compounds, especially when you start late in life. He also explains what to do with the idea right now: stop building random “everything stacks” and start thinking in phases, tracking outcomes, and waiting for real human combo data. -Source: https://www.futura-sciences.com/en/study-finds-drug-combo-could-slow-aging-and-increase-lifespan-by-73_23229/ • ChatGPT Health Turns Your Data Into a Health OS OpenAI launched ChatGPT Health, a dedicated health experience that lets you securely connect medical records and wellness apps like Apple Health and MyFitnessPal, so you can summarize visits, interpret labs, and prepare better questions for your doctor. Dave explains why this is a turning point for quantified self and protocol building: it reduces the friction of pulling data from five different places, and it makes pattern-finding accessible to nontechnical people. He also shares how to use it like a pro: clean inputs, smarter questions, and better doctor conversations. -Source: https://openai.com/index/introducing-chatgpt-health/ • Whole Milk Is Back in Schools The Whole Milk for Healthy Kids Act restores whole and reduced-fat milk options in schools, aligning school nutrition rules with the updated dietary guidelines that no longer treat full-fat dairy like a default villain. Dave breaks down why this matters for child healthspan: satiety and nutrient density drive behavior, learning, and metabolic stability. He also explains why this is a real-world policy experiment worth watching across school districts, and how it can open the door for bigger institutional upgrades like better protein and fewer ultra processed items. -Source: https://www.usda.gov/about-usda/news/press-releases/2026/01/14/whole-milk-back-president-trump-signs-whole-milk-healthy-kids-act • Tirzepatide Trial Targets Biological Age With Aging Clocks A registered clinical trial titled Tirzepatide to Slow Biological Aging is using multiple DNA methylation aging clocks as primary endpoints, along with functional metrics like grip strength and a 6-minute walk test. Dave explains why this is a big maturity step for longevity science: instead of assuming metabolic improvement equals slower aging, this study is measuring biological age directly, across multiple clocks, with performance outcomes. He also shares the practical lesson for biohackers: stop relying on one favorite metric and start thinking in panels, function, and durability of results. -Source: https://clinicaltrials.gov/study/NCT07220473 All source links provided for direct access to the original research and reporting. This episode is designed for biohackers, longevity seekers, and high-performance listeners who want practical strategies rooted in cutting-edge science. Host Dave Asprey translates emerging research into actionable upgrades for your biology, from metabolism and food policy to AI-driven tracking, institutional nutrition, and biological aging measurement. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: Dietary Guidelines for Americans 2025-2030, real food policy reset, ultra processed foods policy, added sugar limits, sugary drinks guidelines, school lunch nutrition policy, SNAP WIC nutrition impact, USDA HHS dietary guidelines 2026, whole food protein guidelines, full fat dairy guidelines, oxytocin aging study, A5i lifespan extension, frail elderly mice lifespan 73 percent, combination longevity therapies, aging intervention synergy, staged longevity protocols, functional aging biomarkers, ChatGPT Health launch, OpenAI health records AI, Apple Health ChatGPT integration, MyFitnessPal ChatGPT integration, AI lab interpretation, AI doctor visit summary, quantified self AI tools, Whole Milk for Healthy Kids Act, whole milk back in schools, school dairy policy change, child satiety nutrition, school meal regulations USDA, tirzepatide biological aging trial, GLP-1 GIP longevity, epigenetic aging clocks trial, DNAmAge PhenoAge GrimAge DunedinPACE, grip strength aging endpoint, 6 minute walk aging endpoint, biological age measurement, longevity clinical trial endpoints, biohacking news update, longevity policy shifts, metabolic health upgrades Thank you to our sponsors! -BEYOND Conference 2026 | Register now at https://beyondconference.com/ -EMR-Tek | https://www.emr-tek.com/DAVE and use code DAVE for 40% off Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps:0:00 - Intro0:19 - New Dietary Guidelines2:09 - Longevity Research Breakthrough3:41 - ChatGPT Health Launch5:10 - Whole Milk Returns to Schools6:29 - GLP-1 Aging Trial7:34 - Weekly Upgrade Protocol9:09 - OutroSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Mark, Kate, Henry and Gary as they discuss 4 new POEMs (Patient Oriented Evidence that Matters, studies with the potential to change practice): a summary of the evidence on tirzepatide (Zepbound) for weight loss, using the Beers list with your patients, high vs standard dose flu vaccine and the risk of hospitalization, and whether stent or endarterectomy are better than maximal medical therapy for patients with asymptomatic carotid stensosis. Here are the links:Essential Evidence Plus: www.essentialevidenceplus.comTirzepatide systematic review: https://pubmed.ncbi.nlm.nih.gov/41015578/ Tirzepatide vs dulaglutide: https://pubmed.ncbi.nlm.nih.gov/41406444/Applying the Beers list: https://pubmed.ncbi.nlm.nih.gov/40697073/ High vs standard dose flu vaccine: https://pubmed.ncbi.nlm.nih.gov/41115437/ Another high dose flu trial: https://pubmed.ncbi.nlm.nih.gov/39230284/ Asymptomatic carotid stenosis treatment: https://pubmed.ncbi.nlm.nih.gov/41269206/

Most people think they go into your body and make all new tissue… but in actuality, they are a delivery mechanism of growth factors. I call them the ultimate traffic cop. In this episode, the host converses with Dr. Jesse Morse, a physician specializing in regenerative and anti-aging medicine. They delve into the intricacies of stem cells and their various sources, including bone marrow, fat, and donor tissue.  Dr. Morse highlights the role of exosomes and growth factors in the healing process. The discussion also focuses on the prevention and treatment of Achilles tendon tears, emphasizing the importance of blood supply, proper diagnosis, and innovative therapies. Additionally, they explore the benefits and applications of various peptides, including BPC 157, TB 500, and MotC, for enhancing healing, anti-aging, and overall health. Dr. Morse also addresses the significance of nutrition and detoxification in maintaining optimal health and preventing injuries. Dr. Jesse Morse is a Miami-based, double board-certified physician in Family and Sports Medicine who specializes in regenerative medicine, injury recovery, and longevity. Since shifting from traditional sports medicine in 2020, he has focused on non-surgical approaches to tendon and ligament injuries using therapies like PRP, stem-cell–based treatments, exosomes, and peptides, alongside functional and anti-aging strategies centered on mitochondrial health, immune support, toxin reduction, and personalized recovery—helping everyone from active adults to high-performance athletes restore function and prevent major injuries like Achilles tears while educating widely online. Connect with him on: Instagram: https://www.instagram.com/drjessemorse/ — Sports medicine, regenerative medicine & insights Linktree (aggregated links to socials & resources): https://linktr.ee/DrJesseMorse   Supplements, Compounds & Peptides Collagen (protein / connective tissue support): https://www.ncbi.nlm.nih.gov/books/NBK507922/ Vitamin C (collagen activation / antioxidant): https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/ Creatine (muscle & mitochondrial support): https://ods.od.nih.gov/factsheets/Creatine-HealthProfessional/ BPC-157 (peptide – tendon & gut healing): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504390/ TB-500 / Thymosin Beta-4 (peptide – tissue repair): https://pubmed.ncbi.nlm.nih.gov/22674782/ GHK-Cu (copper peptide – skin, joints, stem-cell signaling): https://pubchem.ncbi.nlm.nih.gov/compound/GHK-Cu MOTS-c (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/25174616/ SS-31 / Elamipretide (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/29515116/ Thymosin Alpha-1 (immune modulation peptide): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367996/ LL-37 (antimicrobial / immune peptide): https://pubmed.ncbi.nlm.nih.gov/15184378/ 5-Amino-1MQ (NNMT inhibitor / fat loss): https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1MQ N-Acetylcysteine (NAC – liver & detox support): https://www.ncbi.nlm.nih.gov/books/NBK537183/ Glutathione (antioxidant / detox): https://ods.od.nih.gov/factsheets/Glutathione-HealthProfessional/ NAD⁺ / NMN / NR (mitochondrial & anti-aging support): NMN: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-mononucleotide NR: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-riboside Regenerative & Injection Therapies PRP – Platelet-Rich Plasma: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990861/ Bone Marrow–Derived Stem Cells (BMAC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630382/ Adipose-Derived Stem Cells: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416130/ Amniotic / Placental Tissue Products: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124018/ Exosomes (cell signaling vesicles): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465611/ Ultrasound-Guided Injections: https://radiopaedia.org/articles/musculoskeletal-ultrasound-guided-injection Needle Tenotomy (scar-tissue disruption): https://pubmed.ncbi.nlm.nih.gov/30428129/ Detox, Blood & Environmental Interventions Sauna (heat detox & cardiovascular benefit): https://www.health.harvard.edu/staying-healthy/saunas-and-your-health Binders – Modified Citrus Pectin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452227/ GI Detox / Toxin Binders (general concept): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654245/ Heavy Metal Chelation (DMPS concept): https://pubmed.ncbi.nlm.nih.gov/12198644/ Mercury Toxicity: https://www.cdc.gov/mercury/index.html Microplastics in Humans: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068600/ EBOO Therapy (ozone-based blood filtration): https://pubmed.ncbi.nlm.nih.gov/36681461/ Therapeutic Plasma Exchange (TPE): https://www.ncbi.nlm.nih.gov/books/NBK557561/ INUSpheresis (advanced plasma filtration): https://pubmed.ncbi.nlm.nih.gov/37324197/ Medications & Drug Classes Mentioned Corticosteroids (Prednisone – tendon risk): https://medlineplus.gov/druginfo/meds/a601102.html Fluoroquinolone Antibiotics (tendon rupture risk): https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-fluoroquinolone-antibiotics GLP-1 Agonists (Semaglutide / Tirzepatide / Retatrutide discussion): Semaglutide: https://pubmed.ncbi.nlm.nih.gov/36421543/ Tirzepatide: https://pubmed.ncbi.nlm.nih.gov/35220624/ Nutrition & Food-Related Mentions Protein Intake & Muscle Health: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566799/ American Gluten vs European Wheat: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799814/ Seed Oils & Inflammation (discussion topic): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196963/ Dairy & Inflammation (contextual mention): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122229/ Key Mechanisms & Concepts Poor Blood Supply in Achilles Tendon (Watershed Zone): https://pubmed.ncbi.nlm.nih.gov/17021202/ Mitochondrial Dysfunction & Aging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843959/ Stem Cells as "Medicinal Signaling Cells": https://pubmed.ncbi.nlm.nih.gov/25784997/   Show Notes 00:00 Introduction to Exosomes and Stem Cells 01:01 Dr. Morse's Background and Transition to Regenerative Medicine 02:03 Achilles Tendon Tears: Causes and Prevention 05:02 Preventative Measures and Treatments for Achilles Injuries 10:26 The Role of Nutrition in Tendon Health 12:53 Peptides and Their Impact on Tendon Health 15:50 Stem Cells: Misconceptions and Applications 20:52 Comparing Stem Cell Sources and Their Potency 29:52 The Controversy of International Stem Cell Treatments 34:04 Cleaning Toxins from Your Blood 34:19 The Toxic Burden in Our Environment 35:57 Practical Detox Methods 37:47 Mercury and Heavy Metal Testing 44:47 The Problem with American Gluten 46:49 Underrated Peptides for Health 53:42 Growth Hormone and Anti-Aging 01:03:34 Advanced Blood Cleaning Techniques 01:04:51 Conclusion and Contact Information   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

I recently read something that stopped me in my tracks: being fat robbed me of my femininity.And I haven't been able to shake it.In this episode, I pose a question that came out of a Reddit thread but really speaks to a shared experience so many of us quietly lived: growing up, did femininity ever feel like it wasn't meant for you?I'm sharing my own experiences of being invisible next to friends, being talked about like I wasn't even a person, not being able to shop where other girls shopped, missing out on certain “girlhood” moments, and learning very early on which bodies were allowed to be soft, desired, and feminine and which weren't.We'll talk about how those moments shape us long after childhood, how confidence can coexist with old wounds, and what it actually looks like to take your femininity back without performing it or earning permission.If you've ever felt like girlhood passed you by, or like femininity came with conditions you didn't meet, this episode is for you. You're not alone—and you didn't imagine it.Show Notes!

In this episode, I'm sharing my real-life “vacation ready body” routine and the things that help me feel confident heading into a trip, especially when swimsuits are involved.I'm talking about what I'm finally doing differently for myself: my GLP-1 journey (specifically tirzepatide), how it's supported my insulin sensitivity, and the mindset shift that's come with choosing a new kind of care for my body. Plus, I'm breaking down my go-to glow up staples before I travel: my favorite Sun Tan City spray tan (yes, I always do double legs), the workouts I actually stick with: HOTWORX, walking with my weighted vest, and my Peloton Tread routine.Buy Me A Coffee: https://buymeacoffee.com/kelseygravesFollow me on Instagram: https://www.instagram.com/kelsey_gravesFollow me on TikTok: https://www.tiktok.com/@mskelseygravesJoin us in the Trip Tales Podcast Community Facebook Group: https://www.facebook.com/groups/1323687329158879Mentioned in this episode:- Tiffany Balin, NP (https://www.instagram.com/tiffanybalin_np) with Salus Integrative (https://www.salusintegrative.health/)- Insulin Sensitivity and Hypoglycemia- GLP-1s: Tirzepatide and Semaglutide- Sun Tan City Spray Tan: Catalina tint, dark, double legs- HOTWORX- Weighted vest walks- Peloton Tread- Laser Hair Removal- Mel Robbins quote

Dr. Centor discusses the comparative risk for severe gastrointestinal adverse events associated with dulaglutide, semaglutide, and tirzepatide with Dr. Wajd Alkabbani.

If you're a midlife woman who feels like you're doing everything right — lifting weights, eating well, walking, managing stress — and your body still isn't responding, this episode is for you.In this powerful, myth-busting conversation, I'm joined by Dr. Rocio Salas-Whalen, a triple board-certified endocrinologist, obesity medicine specialist, author, and early adopter of GLP-1 therapies in the U.S. Dr. Salas-Whalen helps us understand why weight gain in midlife is not a willpower problem — it's a biology problem.We break down:Why midlife metabolism changes so dramatically during perimenopause and menopauseHow GLP-1 medications actually work (in plain English)Why muscle is the true organ of longevity — and how to protect it while using GLP-1sThe truth about side effects like hair loss, nausea, and “Ozempic face”Microdosing vs. full dosing, long-term use, and what's coming next in obesity medicineWhy shame-based weight loss advice is outdated — and harmfulWe also talk about Dr. Salas-Whalen's new book, Weightless, a science-backed, compassionate guide to GLP-1 medications and metabolic health that validates what so many women have experienced for decades. You can find Weightless wherever books are sold.This episode is about options, not pressure. Facts, not fear. And building health for the long game.Instagram https://www.instagram.com/drsalaswhalen/Website https://www.nyendocrinology.com/_________________________________________1:1 health and nutrition coaching or Faster Way - Reach me anytime at mailto:mfolanfasterway@gmail.com If you're doing “all the right things” and still feel stuck, it may be time to look deeper. I've partnered with EllieMD, a trusted telehealth platform offering modern solutions for women in midlife—including micro-dosed GLP-1 peptide therapy—to support metabolic health and longevity. https://elliemd.com/michelefolan - Create a free account to view all products. ✨ Sign up for my weekly newsletter: https://michelefolanfasterway.myflodesk.com/i6i44jw4fq

This week, primary care physicians Kate Rowland, Mark Ebell, Gary Ferenchick and Henry Barry tackle 4 new practice changing studies (POEMs): bathing frequency for people with eczema, tirzepatide in obese children and adolescents with T2DM, a new flu vaccine, and whether beta-blockers still matter after MI.

Midlife weight gain, burnout, and metabolic changes often get mislabeled as willpower issues. This episode challenges the oversimplified weight loss narrative and unpacks why many women feel blindsided by changes even when their habits stay solid.We dive deeper into this in the Broads episode with Dr. Tyna Moore. We also chat about why GLP-1 was never meant to be a vanity weight loss tool, why microdosing doesn't mean what most people think it means, and the real risks of frailty and why strength equals long-term freedom.Dr. Tyna Moore is a Licensed Naturopathic Physician and Chiropractor with over 30 years in the medical field, specializing in holistic regenerative and metabolic medicine. She earned her degrees from the National College of Natural Medicine and the University of Western States Chiropractic College. Dr. Tyna is also the host of The Dr. Tyna Show and an international speaker.What's Discussed:(08:48) How being “early” to the GLP-1 conversation led to backlash and burnout(10:49) How GLP-1 became misused and distorted by telemedicine and influencers(15:18) Why midlife weight gain isn't about willpower but a neurological shift(16:09) The idea of functional deficiency and why modern stress breaks signaling(19:15) How GLP-1 can increase motivation to move through brain plasticity(22:20) How GLP-1 can magnify existing hormonal deficiencies in women(24:11) Why movement is essential for gut health and metabolic signaling(28:01) Why microdosing is not a true weight loss strategy(35:44) Why strength training is non-negotiable for women in midlife(39:02) The real risks of frailty, hip fractures, and loss of independenceCheck out more from Broads:Website: www.broads.appInstagram: @broads.podcast @broads.appCheck out more from Tara LaFerrara:Website: www.taralaferrara.comInstagram: @taralaferraraYoutube: @TaraLaferraraTiktok: @taralaferraraCheck out more from Dr. Tyna, ND, DC:Website: www.drtyna.comInstagram: @drtynaYoutube: @drtyna

This issue will review: 1.     Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 2.     SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 3.     Continuous SGLT-2, GLIP-1RA and Frailty Progression in Older Adults with Type 2 Diabetes   4.     Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 5.     Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial 6.     Listening to Hypoglycemia: Voice as a Biomarker for Detection of a Medical Emergency Using Machine Learning Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

A large cardiovascular outcomes trial in high-risk adults with type 2 diabetes showed that a dual incretin therapy was noninferior to an established comparator for major adverse cardiovascular events over four years, with similar overall safety but more gastrointestinal side effects and no added cardiovascular benefit. Separate trials demonstrated that a single-bolus thrombolytic was as effective and safe as standard infusion therapy for acute ischemic stroke while simplifying workflows, and that vascular brain injury and inherited risk independently increase dementia risk, underscoring the importance of aggressive management of modifiable vascular factors.

Broadcast from KSQD, Santa Cruz on 12-18-2025: Dr. Dawn opens by examining how market competition is actually working in the weight loss drug sector. Novo Nordisk's Ozempic and Wegovy compete against Eli Lilly's Monjaro and ZepBound, with prices dropping nearly 50% as companies launch direct-to-consumer websites. The main barriers remain needles and refrigeration, driving development of oral versions. Novo's Wegovy pill awaits FDA approval for early 2026 launch at $150 monthly. Next-generation drugs show remarkable results: Eli's retatrutide causes 24% weight loss in 48 weeks, while Novo's Cagrisema combines semaglutide with amylin to reduce muscle loss. Pfizer paid $10 billion for Metsera's once-monthly drug despite significant side effects. A quick fiber tip suggests adding plain psyllium to morning coffee for cardiovascular and microbiome benefits. Start with half a teaspoon and work up to two teaspoons (10 grams) over several weeks to avoid gas. The prebiotic fiber improves glucose tolerance and may reduce cancer risk. UC San Diego scientists discovered why cancers mutate so rapidly despite being eukaryotic cells with protected chromosomes. The answer is chromothripsis, a catastrophic event where the enzyme N4BP2 literally explodes chromosomes into fragments. These reassemble incorrectly, generating dozens to hundreds of mutations simultaneously and creating circular DNA fragments carrying cancer-promoting genes. One in four cancers show evidence of this mechanism, with all osteosarcomas and many brain cancers displaying it. This explains why the most aggressive cancers resist treatment. Research from 2013 shows any glucocorticoid use significantly increases venous thromboembolism risk, with threefold increases during the first month of use. The risk applies to new and recurrent clots, affecting both oral and inhaled steroids, though IV poses highest risk and topical the lowest. Joint injections fall somewhere between inhaled and oral. Anyone with prior blood clots should avoid steroids except for life-threatening situations like severe asthma attacks requiring ventilation. A meta-analysis of 20 randomized controlled trials shows creatine supplementation helps older adults (48-84) maintain muscle mass when combined with weight training two to three times weekly. The supplement provides no benefit without exercise. Recommended dosing starts at 2 grams and works up to 5 grams daily. Vegans benefit most since they consume little meat or fish. Important caveat: creatine throws off standard kidney function tests (creatinine), so users should request cystatin C testing instead for accurate renal health assessment. A new JAMA study suggesting risk-based mammogram screening is fatally flawed. First, researchers offered chemopreventative drugs like tamoxifen only to the high-risk group, contaminating the study design. Second, the demographics skewed heavily toward white college-educated women, missing the reality that Black women face twice the risk of aggressive breast cancer with 40% higher mortality. Third, wild-type humans failed to follow instructions—low-risk women continued getting annual mammograms anyway while high-risk women skipped recommended extra screenings. The conclusion of "non-inferior" outcomes is meaningless given poor adherence. Stick with annual mammograms, and consider alternating with MRIs for high-risk women. The EAT-Lancet report condemns red meat based purely on observational data showing correlations with heart disease, cancer, and mortality. But people who eat lots of red meat differ dramatically from low consumers: they weigh more, smoke more, exercise less, and eat less fiber. Studies can't control for sleep quality, depression, or screen time. Notably, heavy meat eaters also die more in accidents, suggesting a risk-taking lifestyle phenotype. The inflammatory marker TMAO is higher in meat eaters, but starch is also pro-inflammatory. Eating red meat instead of instant ramen might improve health. A balanced diet with limited amounts beats epidemiology-based blanket statements. Dr. Dawn grades Dr. Oz's performance as CMS administrator. Starting at minus one for zero relevant experience, he earns plus two for promoting diet, exercise, and gut health on his show. He studied intensively after nomination, calling all four previous CMS directors repeatedly and surrounding himself with experienced staff (plus one). He finalized Medicare rules favoring prevention over surgery and earned bipartisan praise as "a real scientist, not radical" (plus one). He divested healthcare holdings but kept some blind trust interests (minus 0.5). He's developing a CMS app and partnering with Google on a digital health ecosystem (plus one), but supports ending ACA subsidies that will raise premiums for millions (minus one). He correctly promoted COVID vaccines and contradicted Trump's Tylenol-autism claims (plus one). Final score: 3.5 out of 5 possible points, the only positive score for any Trump health administrator.

Send us a textWelcome back Rounds Table Listeners! In our year-end episode, Drs. Mike and John Fralick discuss five important research studies published in 2025:Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO) (0:00 – 4:20)Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) (4:21 – 9:30)Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) (9:31 – 15:03)Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial (FRESH-UP) (15:04 – 18:09)Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) (18:10 – 23:49)The Good Stuff (23:50 – 25:27):Toronto Star Santa Claus Fund, Calgary Food Bank, The War Amps Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dawson Weiss Guest Episode on The Steroids Podcast Dan and Bodybuilder Dawson Weiss discussed various aspects of bodybuilding, including the effects of different compounds like Retatrutide and Tirzepatide on body composition and performance. Dawson Weiss shared his personal experiences with competing in bodybuilding shows and transitioning between different steroid cycles, while also discussing his current approach to training and diet. They explored the evolution of bodybuilding aesthetics and the challenges of maintaining a competitive mindset, with Dawson expressing his preference for a more natural and balanced physique rather than extreme measures.My Book: ULTIMATE GUIDE TO ROIDS #1 BOOK ON TRUTH IN THE HISTORY OF BODYBUILDING Link -⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bodybuilderinthailand.com/ultimate-guide-to-roids/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Daily Text Msg Training $99usd/month and 1 Hour Phone Call Consult $59usd Email to inquire about personal training to steroidspodcast@gmail.comBodybuilder in Thailand on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/bodybuilderinthailand/⁠⁠⁠⁠⁠⁠My Other Podcast: Grab the Bull Podcast: ⁠⁠⁠⁠⁠⁠https://youtu.be/X6SzfCrN4NY?si=Ho2T9WIVxLjXo_AE⁠⁠⁠Dawson Weiss on Instagramhttps://www.instagram.com/accounts/dawson_m_weissTimestamps: 0:00 Retatrutide Results and Thoughts after extended long term use.4:00 Thought of tirzepatide 8:15 Downsizing on the muscle fullness and freakiness a bit after first bodybuilding competition9:00 First Bodybuilding Competition Experience14:07 Being able to enjoy bodybuilding 15:58 Taking a break from HGH and Insulin20:20 Using testosterone and Deca NPP nandrolone now, current cycle26:00 Dawson seems to do well with high estrogen and progesterone and even takes tablets of Methyl Estradiol on cycle27:35 Bought a new house with his Fitness Influencer money30:45 Bodybuilding Food talking about current Diet36:00 Talking about Ronnie Coleman's legendary Mr Olympia Diet38:30 Discussion on Diuretics Use in Bodybuilding41:20 More Thoughts on Nandrolone, Primobolan and Trenbolone46:45 Bodybuilding Plans for 202649:40 Negative Cosmetic effects of Growth Hormone and Insulin58:04 Dorian Yates role in taking bodybuilding image from being having fun in the sun with girls, to this dark dungeon misery and maximum suffering sport.This Podcast is for entertainment and conversational purposes only. Serious Injury and Death can occur from utilizing chemical performance enhancement. This author does not support the use of illegal performance enhancing drugs. If any substances mentioned in this video are illegal in your country do not use them. The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of transformative events shaping the future of drug development, patient care, and global healthcare strategies.**Johnson & Johnson's Multiple Myeloma Advances** Johnson & Johnson has made significant strides in the treatment of multiple myeloma with their bispecific antibody, Tecvayli. In recent trials, Tecvayli has shown remarkable promise when used in combination therapies as a second-line treatment. This development is noteworthy as it could potentially challenge the dominance of CAR-T cell therapies like J&J's Carvykti by offering a more accessible and less complex alternative. For patients, this means potentially fewer logistical hurdles and a more straightforward therapeutic option, which could drastically improve patient care standards.**Regulatory Scrutiny on RSV Vaccines** Turning to regulatory news, the U.S. FDA has intensified its scrutiny of respiratory syncytial virus (RSV) vaccines developed by pharmaceutical giants such as Merck, AstraZeneca, and Sanofi for infants. This increased oversight follows reports linking some COVID-19 vaccines to adverse effects in children. The FDA's actions highlight the ongoing necessity for vigilant safety monitoring in vaccine development, especially for vulnerable populations like infants. This is a crucial step in ensuring that vaccines designed for our youngest population are both safe and effective.**Eli Lilly's Strategic Moves in Oncology and Beyond** Eli Lilly is making waves in oncology with its BTK inhibitor, Jaypirca. Despite strong phase 3 results that support its use as a first-line treatment for chronic lymphocytic leukemia (CLL), Lilly is focusing on its application as a second-line therapy. This strategic choice reflects an astute understanding of market dynamics and therapeutic niches where Jaypirca can provide substantial benefits despite competition from established first-line treatments. Additionally, Eli Lilly continues to leverage its financial success from its weight loss drug Tirzepatide to position itself as a central player in global pharmaceutical innovation. The company's strategic investments are likely to catalyze advancements across various therapeutic areas, reinforcing its role as a key contributor to medical breakthroughs.**Legislative Impact on Biopharma** In legislative news, the Biosecure Act's incorporation into the U.S. National Defense Authorization Act marks a strategic shift towards tightening regulations on Chinese biopharma entities regarding federal contracts by 2026. This move could have profound implications for international collaborations and competition within biotechnology innovation and drug development sectors. It signals a broader trend of increased scrutiny on foreign entities in sensitive industries like biopharmaceuticals.**China's Healthcare Transformation** China's healthcare landscape is undergoing significant transformation with the inclusion of drugs from companies like Pfizer, Lilly, and J&J into its first private insurance formulary. This development could enhance access to innovative medications within China, potentially improving health outcomes and influencing global pricing strategies in the pharmaceutical industry.**Gamida Cell's Milestone in Cell Therapies** In a major milestone for cell therapies, Gamida Cell has secured a second FDA approval for its stem cell therapy Omisirge. Initially approved to reduce infection risk during hematopoietic stem cell transplantations in blood cancer patients, Omisirge's expanded indication to treat severe aplastic anemia underscores the potential of cell therapies in addressing diverse hematologic conditions.**CSL Seqirus' New Facility in Australia** In Australia, CSL Seqirus has opened a $1 billion facility dedicated to producing cell-baSupport the show

Chris Duffin sits down with Bizzie Gold, creator of the Break Method and author of "The Mind is a Filthy Liar," for a deep dive into the power of subconscious coding and emotional rewiring. If you've ever wondered why high achievers can succeed outwardly while struggling internally, or how to get unstuck from self-sabotaging patterns, this episode brings the answers. Bizzie Gold shares her unique, data-driven approach to identifying and breaking self-deceptive mental habits—going well beyond traditional therapy. She opens up about her own transformative journey, growing up in a household shaped by mental health challenges, and how a chance encounter with mushrooms and the movie Fight Club at 13 reshaped her worldview.

The cozy, magical season is here! Leggings, sweaters, cookies, hibernation mode. But this can also become the season where we disconnect from our bodies without even realizing it.In this episode, I'm sharing a truth we don't talk about enough:✨ The longer you hide in leggings and oversized sweatshirts, the longer you stay in denial about where you really are physically and emotionally. ✨ Getting dressed, putting on makeup, and wearing a real outfit isn't about vanity… it's about awareness, identity, and showing up for yourself. ✨ And what I don't want is for you to “wake up” in spring only to realize nothing fits and you don't recognize yourself.Let's talk about how you can stay connected, confident, and present with yourself even during cozy season so you don't lose yourself in the process.

In this bonus episode of A Friend for the Long Haul, I get to talk with Dr. Julia Moore Vogel from Scripps Research. I slid into her DMs to see if she'd like to join me to discuss the recruitment and structure of a new clinical trial examining the effects of tirzepatide, a dual GLP-1 and GIP agonist, on long COVID symptoms. Dr. Vogel is the Senior Program Director, The Participant Center, All of Us Research Program. She's a fellow long hauler and "manages The Participant Center (TPC) for the All of Us Research Program which is charged with recruiting and retaining 350,000 individuals that represent the diversity of the United States. TPC aims to make it possible for interested individuals anywhere in the US to become active participants, for example by collaborating with numerous outreach partners to raise awareness, collecting biosamples nationwide, returning participants' results and developing self-guided workflows that enable participants to join whenever is convenient for them." (Thanks for letting me borrow the blurb, Scripps.

Before we all slip into our cozy clothes and head toward the candied yams, I wanted to drop in with a quick Thanksgiving episode and a little love note from my heart to yours.Today, I'm sharing what I'm truly grateful for this season: you. Thank you for listening, for hanging with me through the messy seasons, the comebacks, the pauses, the growth, and all the moments in between. This community means more to me than I can ever put into words.I'm also talking about the real-life chaos of the holidays, the emotional weight many of us carry into this week, and some gentle reminders about food, body image, and giving yourself permission to just be you. You don't need to earn your Thanksgiving meal. You don't need to restrict. You don't need to go overboard. You're allowed to enjoy your plate, be present with your people, and let go of the guilt that diet culture tries to hand you.Take what you need, leave what you don't, and know that you're not alone.Wishing you a happy Thanksgiving filled with yummy food, core memories, and zero shame. I'm so grateful for you. 

In this episode, Dr. Taves and Dr. Sarah Thomas explore how GLP-1 weight loss drugs—such as Ozempic, Wegovy, and Mounjaro—may influence headaches and migraines. They break down how these medications work in the body, how blood sugar stability impacts migraine symptoms, and why some people notice improvement while others experience worsening headaches.They also discuss an important but often overlooked consideration: even if GLP-1 medications help with weight loss or migraine symptoms, there may be other factors to think about before relying on them long-term. From side effects to the difference between symptom management and addressing the root cause, this episode helps listeners understand the full picture so they can make informed decisions.Novera: Headache Center

Welcome back to Ozempic Weight Loss Unlocked, the show where we break down the latest developments in weight loss medications and what they mean for your health. I'm your host, and today we're diving into some exciting new data and industry shifts that you need to hear about.Let's start with what's happening right now in the weight loss medication world. A recent systematic review of over forty thousand adults found that semaglutide and tirzepatide significantly outperform older medications in achieving meaningful weight loss. In clinical trials, semaglutide resulted in a fourteen point nine percent reduction in body weight over sixty eight weeks, while tirzepatide led to a twenty point nine percent reduction. That's substantial progress compared to earlier options like liraglutide, which delivered only four to five percent weight loss.But here's something important our listeners need to understand: clinical trial results don't always match real world outcomes. When researchers looked at actual users after one year, those taking semaglutide lost seven point seven percent of their body weight, and those on tirzepatide lost twelve point four percent. Why the difference? About fifty percent of patients discontinued treatment during that first year, and eighty percent took lower dosages than prescribed.Speaking of usage, the numbers are staggering. Approximately one in eight American adults, or around twelve percent, have used a glucagon like peptide one medication at some point. Among people diagnosed with diabetes, that number jumps to forty three percent. The average age of users in the United Kingdom is forty four years old, with people aged forty to fifty nine making up more than half of all users.Now let's talk money, because cost remains a major barrier. The monthly out of pocket cost for Ozempic in the United States can reach as high as twelve hundred dollars for uninsured individuals. This pricing has created a competitive marketplace. In November twenty twenty five, Pfizer won a bidding war with Novo Nordisk to acquire obesity drug developer Metsera, giving them injectable and oral glucagon like peptide one candidates expected to enter clinical trials soon.But there's even more competition coming. Research indicates that several pharmaceutical companies including AstraZeneca, Zealand Pharma, Roche, and Amgen are expected to enter the glucagon like peptide one market with multiple drug launches planned between twenty twenty seven and twenty thirty two.Interestingly, a new alternative is emerging. A medication called eloralintide, which targets a different hormone called amylin instead of glucagon like peptide one, showed promising results. In a phase two clinical trial with two hundred sixty three participants, those receiving eloralintide experienced average weight loss between nine and twenty percent after forty eight weeks, compared to only zero point four percent in the placebo group. Up to ninety percent of participants on eloralintide improved by at least one body mass index category, and the study showed improvements in cardiometabolic risk factors including waist circumference, blood pressure, and blood sugar management.Our listeners should know that not everyone responds equally to these medications. Past studies show that as much as seventeen percent of glucagon like peptide one users may be non responders to the medication. This is why having multiple treatment options with different mechanisms of action matters so much.One final note worth mentioning: the rise in glucagon like peptide one use has sparked increased demand for cosmetic surgeries to remove loose skin following significant weight loss. Procedures like arm lifts, thigh lifts, and tummy tucks have all seen increased demand.Thank you so much for tuning in to Ozempic Weight Loss Unlocked. Please make sure to subscribe so you don't miss our next episode covering even more developments in this rapidly evolving space. This has been a Quiet Please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this episode of Ageless Future, Cade Archibald dives deep into the growing world of GLP-1 peptides—like Semaglutide (Ozempic), Tirzepatide, and the newest, Retatrutide. He breaks down the science, benefits, and potential risks of these game-changing therapies for weight loss, blood sugar control, and metabolic health. Cade exposes common mistakes that lead to side effects such as muscle loss and GI issues, emphasizing the critical role of proper dosing, receptor resets, and stacking with supportive peptides. Most importantly, he outlines how combining these peptides with smart nutrition, strength training, and personalized care can create lasting, transformative results—avoiding the pitfalls of mainstream misuse and fad weight-loss hype. LIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/

NEW SEASON ~ EPISODE 5Kiki sits down with Shelbi Sloan who discusses integrating wellness into your medical aesthetic practice, including adding peptides/weight loss, and hormones into your practice seamlessly.  Podcast Instagram: @aesthetic.chatwithkiki Host Kiana Gamble Aesthetic Instagram: @aestheticnurse.kikiGuest Instagram Shelbi Sloan: @snatchedbysloanCheck out AESTHETICNURSEKIKI.COMMessage Aesthetic Chat with Kiki

https://www.tadeclinicagem.com.br/guia/?utm_source=whatsapp&utm_medium=social&utm_term=&utm_content=&utm_campaign=Guia-blackfriday&utm_source_platform=&utm_creative_format=&utm_marketing_tactic=

The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬Sophia Ambruso @sophia-kidney.bsky.socialNayan Arora @captainchloride.bsky.socialSpecial Guests Brian Rifkin @brianrifkin.bsky.socialAnna Gaddy @AnnaGaddyEditing and Show Notes byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesBrian Rifkin and Cristina Popa ascend to co-editors in chief of NephJC.Paresh Jadav receives the first NephJC Champion award. Dr. Jadav hosted the NephJC night and saved NephJC thousands of dollars. It makes a huge difference in our fund raising. Thank you.Also a big thank-you to Jade Teakell for buying the cowboy hats!The first pick of the draft, by Sophia is Fish oil for dialysis: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (NEJM)The second pick, by Brian is FINE-ONE (Bayer Press release)Rajiv Agarwal's mediation analysis to show how much of finerenone's beneficial renal effects are captured by the reduction proteinuria: Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis (PubMed)Anna has the third pick and it goes to Katherine Tuttle and the REM0DEL Trial: REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide (Science Direct)Nayan goes off-board and picks a poster by a med student (backed by Testani)Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure (ClinicalTrials.gov)For the final pick in the draft Joel went with a little Lilly on Lilly violence: Tirzepatide vs. Dulaglutide Is Associated with Reduced Major Kidney Events in Patients with Type 2 Diabetes, CVD, and Very High-Risk Kidney Diseases (JASN)Bring out your dead…What's left on the draft board.Liberate-D A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial (JAMA)Atacicept for IgAN A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (NEJM)Lilia Cervantes crushed it with Community Health Worker Support for Hispanic and Latino Individuals Receiving Hemodialysis: The Navigate-Kidney Randomized Clinical Trial (JAMA)Tubular SecretionBrian: Late Breaking and High Impact Clinical Trials. Including Sibe! REGENCY Biopsy Data.Sophia: Flying Home. No, really it's the Electrolyte QuizJoel: The Poster Session, the Quiz Session, and Nayan: Flying to AHA to talk about dual-heart-kidney-transplantAnna: Kidney STARS! and Melanie Hoenig's session on potassium

In this powerful episode of The Determined Society, host Shawn French sits down with Jeffrey Delaney — founder of T Clinics and Nuviva Medical Weight Loss — to talk about what really happens when men lose their edge.Jeffrey breaks down the myths around testosterone, hormone therapy, nutrition, and popular GLP-1 medications like Ozempic and Tirzepatide. Together, he and Shawn unpack what it means to be a modern man — one who leads with strength, vulnerability, and consistency — while challenging the stigma around masculinity and self-care.If you've ever felt stuck, exhausted, or unsure how to get back to feeling like yourself again, this episode will show you where to start and how to take control of your health for good.Key Takeaways-True health isn't just physical — mental clarity begins in the body.-Hormone balance can reignite drive, motivation, and emotional stability.-Quick fixes like GLP-1s work only when paired with movement and nutrition.-Sleep, nutrition, training, and mindset are the four pillars of lasting wellness.-Masculinity isn't toxic — it's essential to family and personal balance.-Comparison kills progress; consistency creates transformation. Connect with me :https://link.me/theshawnfrench?fbclid=PAZXh0bgNhZW0CMTEAAaY2s9TipS1cPaEZZ9h692pnV-rlsO-lzvK6LSFGtkKZ53WvtCAYTKY7lmQ_aem_OY08g381oa759QqTr7iPGAJeffrey Delaneyhttps://linktr.ee/jeffreydelaney?utm_source=linktree_profile_share

Listen in as Kristin chats with Dr Angela Kwong, a Sydney-based General Practitioner with a special interest in medically supervised weight management, about the use of GLP-1 agonists. Dr Kwong serves as the NSW State Lead for the RACGP Specific Interests Group in Obesity Management and works closely with colleagues across disciplines to improve care for people living with obesity. She is also the founder of Enlighten Me, a multidisciplinary online program that provides evidence-based, GP-led support for patients seeking weight management. The program has been recognised for its contribution to patient education and its focus on accessible, stigma-free care. Additional GLP-1 reading: 1. GLP-1 agonist role in renal protection - FLOW Trial 1a. Digestible summary of the FLOW trial 2. Current ANZCA guidelines for anaesthesia / sedation in patients using GLP-1 agonists (May 2025) 3. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

GLP-1 weight loss drugs like Ozempic, Wegovy, and Tirzepatide are being promoted everywhere but what's missing is the full story. This episode breaks down the hidden GLP-1 side effects most women never hear about, from anxiety and dehydration to vision problems, muscle loss, and disordered eating risks. Chalene exposes how influencer affiliate programs and compounding pharmacies are fueling the hype while lawsuits and safety questions grow. You'll learn what informed consent should actually include, how to protect your metabolism, and why women over 40 need to question what's really behind this weight loss craze. Watch this episode on YouTube this Sunday!! 

Send us a textChris Broomhead is a bodybuilder, personal trainer and coach, educator, entrepreneur, and advocate for science-backed performance & health. After 14+ years competing in bodybuilding, he is now dedicated to cutting through hype in health and performance.Today, Chris focuses on GLP-1s and peptides, such as Semaglutide, Tirzepatide, Retatrutide, teaching how science and lifestyle work together for resilience, longevity, and transformation.Find Chris at-IG- @Chris_Broomhead_researchYT- @Chris Broomhead CoachingFind Boundless Body at- myboundlessbody.com Book a session with us here!

After taking some much-needed time off before, during, and after our family cruise, I'm finally back behind the mic — and whew, it's been a minute! In this episode, I'm catching you up on life, how hard it can be to get back into your rhythm, and the lessons I learned along the way.This isn't just a vacation recap. It's a reminder that life is happening right now. You can't wait until you lose the weight or have it all together to make memories. From cruise chaos to core memories, I'm sharing how “someday” never comes, why you should take the trip, and what going with the flow taught me about self-acceptance and joy.Plus, I'll share a few of my favorite Amazon outfit finds and cruise must haves that made the trip easier, cuter, and a little more glam (even in mom mode).

Email List: ⁠https://huntershealthhacks.beehiiv.com/⁠Get My Book On Amazon: ⁠⁠https://a.co/d/avbaV48Download⁠⁠The Peptide Cheat Sheet: ⁠⁠https://peptidecheatsheet.carrd.co/⁠⁠Download The Bioregulator Cheat Sheet: ⁠⁠https://bioregulatorcheatsheet.carrd.co/⁠⁠1 On 1 Coaching Application: ⁠⁠https://hunterwilliamscoaching.carrd.co/⁠⁠Book A Call With Me: ⁠⁠https://hunterwilliamscall.carrd.co/⁠⁠Supplement Sources: ⁠⁠https://hunterwilliamssupplements.carrd.co/⁠⁠Amazon Storefront: ⁠⁠https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY⁠⁠Socials:Instagram: ⁠⁠https://www.instagram.com/hunterwilliamscoaching/⁠⁠Video Topic Request: ⁠⁠https://hunterwilliamsvideotopic.carrd.co/In this episode, I dive deep into what I believe could be the most powerful synergy in the entire world of longevity and metabolic optimization — the combination of SGLT2 inhibitors (like Jardiance and Farxiga) with GLP-1 agonists (like Retatrutide, Tirzepatide, and Semaglutide).These medications were originally created for diabetics, but what we're learning now is that they may be rewriting the entire playbook on healthspan and lifespan extension. I break down the research showing how SGLT2 inhibitors not only lower blood glucose but also improve cardiovascular health, protect the kidneys, reduce inflammation, and even clear senescent cells — all while mimicking the effects of caloric restriction and fasting.Then, I explain how pairing them with a GLP-1 creates a metabolic symphony unlike anything else we've ever seen. Together, they reduce insulin resistance, improve energy metabolism, and activate the same longevity pathways linked to caloric restriction, AMPK activation, and mitochondrial renewal.If you care about living longer, staying leaner, and protecting every organ system in your body, this episode is a must-listen. I share what I've seen personally, what's happening in clinical data, and why I believe the GLP-1 + SGLT2 combo could end up being one of the greatest discoveries in modern medicine for both health and performance.

GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® are changing the weight-loss landscape, but there's more to the journey than watching the scale move. In this episode, we break down 4 essential considerations everyone on a GLP-1 should know.With Mindy's science-based and trustworthy expertise, these are the considerations to protect your health during and after medication use:1. Preventing Lean Muscle Mass loss and Osteoporosis2. Managing GI Issues3. Preventing nutrient deficiencies 4. Build Healthy HabitsThis episode is supportive, judgment-free, and packed with actionable takeaways. Whether you're on a GLP-1, considering one, or supporting someone who is, this conversation will leave you feeling empowered and informed. References:Wong, ND, et al. US Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2023Wong, ND, et al.  Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2024 Chakhtoura, M., et al. Pharmacotherapy of obesity: EClinicalMedicine, 2023 Volek J, et al. Nutritional Considerations During Major Weight Loss.  Curr Nutr Rep. 2024Meslon E, et al.  What is the pipeline for future medications in obesity? Nature. 2024Martin CK, et al.  Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.  Nat Med. 2025Dilly A, et al.  Characteristics and food consumption for current, previous, and potential consumers of GLP-1s.  Food Quality and Preference.  2025;129;105507We are so glad you are here. Want to stay in touch?Follow us on social media: Sweat and Laughter podcast - @sweat.and.laughter.podcast Mindy - @strongover40_dietitian Cheryl - @training.with.cheryl Mindy & Cheryl - @mcfitadventures Email us: mcfitadventures@gmail.com Thank you so much for listening to Sweat & Laughter. M & C

If you've ever wondered why losing weight after 40 feels harder than ever, even when you're doing “all the right things” - you are not alone.In this powerful episode of Nourish with Michelle Fox, I share my personal journey of healing with hormone expert Kimberly Cunningham. We get real about the role hormones play in weight, metabolism, muscle, energy, and cravings…and why willpower is not the problem.It is an honor to open up about my own experience: how I began with lab work and testosterone therapy, and why Kimberly had me wait three months before beginning Tirzepatide. Kimberly's thoughtful and thorough approach made all the difference. No shortcuts - just informed, empowered, medically supervised support.What we cover in Episode 79:• Why traditional weight loss advice fails a lot of women• The hormone–metabolism connection (especially testosterone!)• Michelle's personal journey: labs, then testosterone, then Tirzepatide• How muscle mass and cardio impact longevity• Why community and connection matter for long-term healthShow notes at michellefox.com/podcast! Hosted on Acast. See acast.com/privacy for more information.

Watch Here : https://www.youtube.com/watch?v=uSK7g1_hkfk Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

Howie and Harlan are joined by Nate Wood, a Yale School of Medicine internist and trained chef, to discuss his work combining lifestyle guidance with hands-on training in making healthy, tasty food. Harlan shares new guidance on what counts as a healthy blood pressure; Howie provides an update on rising health insurance costs. Links: Blood Pressure Harlan Kumholz, "Severe Hypertension: The Next Never Event" JACC: 2025 High Blood Pressure Guidelines Resources "Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension" Obesity Drugs "Semaglutide and Tirzepatide for Obesity: Effectiveness and Value" "Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity" Harlan Krumholz and Jason Abaluck, "Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide" Culinary Medicine "Culinary Medicine: The Secret Ingredient to Good Health" American College of Lifestyle Medicine "How each lifestyle medicine pillar supports good nutrition" Dr. John La Puma "What to know about 'hyperpalatable' foods" Food is Medicine Coalition: Our Model American Academy of Family Physicians: Shared Medical Appointments/Group Visits Cleveland Clinic: GLP-1 Agonists Yale New Haven Hospital: Irving and Alice Brown Teaching Kitchen "Bringing Culinary Medicine to Yale's New Teaching Kitchen" Dr. Nate Wood Nate Wood on Instagram Health Insurance Costs Kaiser Family Foundation: 2025 Employer Health Benefits Survey "Health Benefits In 2025: Family Premiums Rise 6 Percent, Large Employers Increase Coverage Of GLP-1s For Weight Loss" "Annual Family Premiums for Employer Coverage Rise 6% in 2025, Nearing $27,000, with Workers Paying $6,850 Toward Premiums Out of Their Paychecks" "8 Things to Watch for the 2026 ACA Open Enrollment Period" "ACA Insurers Are Raising Premiums by an Estimated 26%, but Most Enrollees Could See Sharper Increases in What They Pay" Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Today, we're tackling a question that comes up often in peptide, weight loss, and nutrition clinics: why does one person see great results with semaglutide, while another responds better to tirzepatide—or even retatrutide? If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ All three peptides target the incretin system, but they act in slightly different ways—and those differences can dramatically affect outcomes. Let's start with the basics. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the gut hormone GLP-1, which increases insulin when blood sugar is high (to help lower blood sugar), suppresses glucagon (which also decreases blood sugar), and slows gastric emptying. It also enhances satiety—so you feel full longer and eat less. Tirzepatide is a dual agonist, acting on both GLP-1 and GIP receptors. GIP—glucose-dependent insulinotropic polypeptide—also helps with insulin secretion to lower blood sugar, increases fat metabolism, and may reduce some of the GI side effects seen with GLP-1 alone. Retatrutide, the newest in the lineup, is a triple agonist that targets GLP-1, GIP, and glucagon receptors. Retatrutide lightly activates the glucagon receptor while strongly activating GLP-1 and GIP receptors, which help regulate blood sugar and boost insulin secretion. This keeps blood sugar stable—or even improves it. Beyond blood sugar, glucagon also ramps up metabolism and calorie burning. By gently engaging glucagon receptors, retatrutide can increase energy expenditure and support fat loss without triggering large blood sugar spikes. So how do you decide which one might work best? Let's walk through common clinical situations. Patients with Hypothyroidism Let's talk about hypothyroidism. People with hypothyroidism often have slower metabolism, making weight loss more difficult even with a balanced diet. Low thyroid hormone levels slow calorie burning and energy use, so weight gain can occur more easily. For these patients, semaglutide is a reliable starting point—it helps regulate appetite and caloric intake. If progress plateaus, tirzepatide or retatrutide may provide an edge by boosting energy expenditure and fat oxidation, essentially "jump-starting" a slower metabolism. Patients with PCOS (Polycystic Ovary Syndrome) What about patients with PCOS (polycystic ovary syndrome)? Insulin resistance is common in PCOS, often leading to higher androgen levels (e.g., testosterone) and symptoms like irregular periods, acne, and excess hair growth. Hormonal changes also affect appetite-regulating hormones, increasing hunger and cravings. Both GLP-1 and dual agonists have proven effective in managing metabolic and reproductive aspects of PCOS. Typically, we start with semaglutide to improve weight, insulin sensitivity, androgen levels, and menstrual regularity. After a few months, if weight loss plateaus or cravings remain high, we may switch to tirzepatide. The added GIP activity enhances fat metabolism, insulin control, and may further support hormone regulation and ovulation. The key is starting with what's well-studied and tolerated, then stepping up if additional metabolic or reproductive support is needed. Type 2 Diabetes (T2DM) The next medical condition I'd like to talk about is type 2 diabetes (T2DM). Weight gain in T2DM often stems from insulin resistance. Cells don't respond effectively to insulin, prompting the pancreas to relelase more. High insulin levels encourage fat storage, particularly around the abdomen, while elevated blood sugar can increase hunger and cravings. Some diabetes medications, like insulin or sulfonylureas (e.g., glipizide or glyburide), can also contribute to weight gain. All three drugs lower blood sugar and promote weight loss, but tirzepatide currently shows the strongest combined A1c reduction (average blood sugar over the past 2 to 3 months) and weight loss. GIP and GLP-1 work together to enhance insulin response more effectively than GLP-1 alone. Retatrutide is in phase 3 trials, with potential FDA approval as early as 2027. Its glucagon receptor activity may offer additional glucose regulation and energy expenditure benefits. Patients with >15% Weight Loss Goals Okay, let's talk about weight loss goals and how this ties into the decision process for choosing a weight loss medication. For those patients looking to lose more than 15% of their total body weight, tirzepatide or retatrutide are likely to deliver greater results. Clinical data show semaglutide can achieve up to 15% total weight loss while tirzepatide can achieve up to 22% and retatrutide up to 24%. That said, semaglutide remains a highly effective option for weight loss. However, if progress begins to plateau, transitioning to a dual or triple agonist may help restart weight loss and push past that plateau. Pre- and Postmenopausal Women What about peri- and postmenopausal patients? Hormonal shifts during perimenopause and menopause slow metabolism and can increase cravings. Declining estrogen promotes abdominal fat storage and affects appetite-regulating hormones. Semaglutide helps with appetite control and gradual fat loss, while tirzepatide's GIP activation can further support fat metabolism when estrogen levels drop. Patients with Heart Disease or High Cholesterol The last group of patients I'd like to discuss is patients with heart disease (e.g., heart failure, stroke, heart attack, or even atherosclerosis) or people with high cholesterol. Semaglutide has the strongest cardiovascular outcomes data, reducing major adverse cardiac events by 20% and improving LDL cholesterol (bad cholesterol) and blood pressure. Tirzepatide shows promise for heart and lipid benefits, but those trials are still ongoing. For patients with prior heart attack, stroke, or severe coronary artery disease, semaglutide remains the safest evidence-backed starting point—unless intolerable side effects or weight loss resistance occur. Tolerability Now I want to switch gears a bit and talk about side effects and tolerablity of these peptides. Some patients experience stomach-related side effects like nausea, bloating, or acid reflux on semaglutide. Generally, tirzepatide tends to cause fewer GI side effects, likely due to GIP balancing GLP-1 activity in the gut. So patients struggling with nausea or other stomach-related side effects may find tirzepatide more tolerable. Just something to keep in mind. Individualizing Therapy Lastly, I want to highlight the importance of individualizing weight loss peptide treatments. There's no one-size-fits-all approach when it comes to these therapies. Clinicians should carefully consider a patient's goals, medical history, current medications, and tolerance before choosing the most appropriate option. Setting realistic expectations from the start is essential. It's important to remember that everyone's body responds differently because of factors like hormones, genetics, metabolism, gut microbiome balance, and lifestyle habits. These differences influence how effectively a peptide therapy works and how well it's tolerated. That's why ongoing monitoring and follow-up are such an important part of the process. Providers track progress, adjust dosing when needed, and switch medications if weight loss plateaus or side effects occur. The goal isn't just to lose weight quickly—it's to create a safe, sustainable plan that supports long-term metabolic health and helps patients feel their best. Thanks for listening to The Peptide Podcast.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Until next time, be well, and have a happy, healthy week.

In this episode, we take a closer look at tirzepatide, a type 2 diabetes medication also used to help with weight loss. Postmenopause weight gain can be a normal part of aging, and there are some questions about whether medications like tirzepatide could be useful and safe for postmenopausal women. Host Aaron Lohr talks with Maria Daniela Hurtado Andrade, MD, PhD, assistant professor of medicine at Mayo Clinic Florida, and Regina Castaneda, MD, a research fellow at Mayo Clinic College of Medicine & Science. They presented an abstract at ENDO 2025 titled, “One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women With and Without Hormone Therapy.” Show notes are available at https://www.endocrine.org/podcast/enp105 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

GET EXCLUSIVE OTP SAVINGS! www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

#bodybuilding #TRT #Muscle #Contestprep #bodybuildingpodcastULTIMATE GUIDE TO ROIDS #1 BOOK ON TRUTH IN THE HISTORY OF BODYBUILDING Link -⁠ ⁠⁠⁠⁠⁠https://bodybuilderinthailand.com/ultimate-guide-to-roids/⁠⁠⁠⁠⁠⁠Daily Text Msg Training 99/month and 1 Hour Phone Call Consult 59 Send Email to inquire about personal training to steroidspodcast@gmail.comBodybuilder in Thailand on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/bodybuilderinthailand/⁠⁠⁠⁠My Other Podcast: Grab the Bull Podcast:⁠⁠⁠https://youtu.be/X6SzfCrN4NY?si=Ho2T9WIVxLjXo_AE⁠0:00 Preference for Test Propionate - Combining testosterone propionate and enanthate6:56 1st Cycle Lifting for 4 years natural with gyno from puberty11:41 Dbol Gets a Bunch of Shit Thrown at It14:55 Family Guy using tirzepatide and TRT testosterone. Looking for a good first cycle. Effects of Gear while dieting.19:42 Daily Superdrol as a First Cycle, but not trying to be Huge. Scared of Needles. 28:47 Adding Masteron to get a Big Libido 34:15 Enclomiphene - HCG - Nolvadex for Testosterone Boosting43:13 Testosterone Sustanon and Primo cycle - Sustanon Explained45:25 Old school bodybuilders had better skin49:50 Retatrutide Results - GLP1 Agonists Semaglutide Tirzepatide and Retatrutide ComparedThis Podcast is for entertainment and conversational purposes only. Serious Injury and Death can occur from utilizing chemical performance enhancement. This author does not support the use of illegal performance enhancing drugs. If any substances mentioned in this video are illegal in your country do not use them. The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice.

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Girl, I am so over these creepy AI “fitness” ads. Filters are bad enough but now we have actual robots preaching toxic diet culture BS! It's wild how far we've come from Photoshop and filters — now we're literally being sold body image standards that don't even exist.In this episode, I'm venting (because seriously, what is happening?!) but also unpacking what this means for those of us healing our relationship with our bodies. Because if you're already struggling to feel good in your skin, seeing these fake “fitfluencers” can seriously mess with your head.We'll talk about: 

On today's episode we discuss the latest hot topic in the fitness industry - weight loss drug, Retatrutide. What are the benefits? Are there potential side effects? What does this mean for bikini competitors in prep, dieting hard for a show? Follow us on IG @preplifepodcast @glamgirlbikini @amyehinger @leemarie183 Watch on YouTube: Glam Girl Bikini   Join the team: https://www.glamgirlbi...   1st Phorm Supplements we use: https://1stphorm.com/?... Key references • Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med / related publications (phase-2 reports). • Sanyal AJ, et al. Retatrutide and liver fat/liver outcomes. Nature Medicine 2024. • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP). N Engl J Med 2021. • Jastreboff AM, et al. Tirzepatide once weekly for obesity (SURMOUNT) and related reports. PubMed/NEJM/SURMOUNT analyses. • Conceição-Furber E, et al. Is glucagon receptor activation the thermogenic solution? Frontiers in Endocrinology, review of GCGR and energy expenditure mechanisms. • Frampton J, et al. The acute effect of glucagon on components of energy expenditure. Int J Obes / Nature Metabolism meta-

In this episode of The Jordan Syatt Podcast I speak with the incredible Dr. Danielle Belardo (IG: @daniellebelardomd) about:- The Best Diet for Heart Health- The Truth About LDL Cholesterol- How to Lower Your Blood Pressure- Tirzepatide and GLP-1's for Weight Loss- Menopause Misinformation- How Much Muscle Do You Actually Need for Health?- The Most Important Health Habits for Longevity- And more...I hope you enjoy this episode and, if you do, please leave a review on iTunes or Spotify (huge thank you to everyone who has written one so far).Finally, if you've been thinking about joining The Inner Circle but haven't yet... we have hundreds of home and bodyweight workouts for you and you can get them all here: https://www.sfinnercircle.com/

I'm back from Disney and my brain feels like… pizza.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451 Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year. Episode resource links: Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.  Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217.  Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045.  Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.